Cargando…
Targeting AML through DR4 with a novel variant of rhTRAIL
Despite progress in the treatment of acute myelogenous leukaemia (AML) the outcome often remains poor. Tumour necrosis factor related apoptosis-inducing ligand (TRAIL) is a promising therapeutic agent in many different types of tumours, but AML cells are relatively insensitive to TRAIL-induced apopt...
Autores principales: | Szegezdi, Eva, Reis, Carlos R, van der Sloot, Almer M, Natoni, Alessandro, O’Reilly, Aoife, Reeve, Janice, Cool, Robbert H, O’Dwyer, Michael, Knapper, Steven, Serrano, Luis, Quax, Wim J, Samali, Afshin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394230/ https://www.ncbi.nlm.nih.gov/pubmed/21070598 http://dx.doi.org/10.1111/j.1582-4934.2010.01211.x |
Ejemplares similares
-
The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
por: van Dijk, Marianne, et al.
Publicado: (2011) -
Kinetics in Signal Transduction Pathways Involving Promiscuous Oligomerizing Receptors Can Be Determined by Receptor Specificity: Apoptosis Induction by TRAIL
por: Szegezdi, Eva, et al.
Publicado: (2012) -
Stem cells are resistant to TRAIL receptor-mediated apoptosis
por: Szegezdi, Eva, et al.
Publicado: (2009) -
Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL
por: Meijer, A, et al.
Publicado: (2013) -
Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants
por: Reis, C R, et al.
Publicado: (2010)